var data={"title":"Procainamide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Procainamide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6841?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">see &quot;Procainamide: Drug information&quot;</a> and <a href=\"topic.htm?path=procainamide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Procainamide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709347\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug-induced lupus erythematosus-like syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The prolonged administration of procainamide often leads to the development of a positive antinuclear antibody (ANA) test, with or without symptoms of a lupus erythematosus-like syndrome. If a positive ANA titer develops, the benefits versus risks of continued procainamide therapy should be assessed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicenter, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or nonfatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to matched placebo-treated group (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The applicability of the cast results to other populations (eg, those without recent myocardial infarctions) is uncertain. Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of procainamide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Blood dyscrasias:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Agranulocytosis, bone marrow depression, neutropenia, hypoplastic anemia and thrombocytopenia in patients receiving procainamide HCl have been reported at a rate of approximately 0.5%. Most of these patients received procainamide within the recommended dosage range. Fatalities have occurred (with approximately 20 to 25% mortality in reported cases of agranulocytosis). Since most of these events have been noted during the first 12 weeks of therapy, it is recommended that complete blood counts including white cell, differential and platelet counts be performed at weekly intervals for the first 3 months of therapy, and periodically thereafter. Complete blood counts should be performed promptly if the patient develops any signs of infection (such as fever, chills, sore throat or stomatitis), bruising or bleeding. If any of those hematologic disorders are identified, procainamide therapy should be discontinued. Blood counts usually return to normal within 1 month of discontinuation. Caution should be used in patients with preexisting marrow failure or cytopenia of any type.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213545\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Procainamide;</li>\n      <li>Procainamide Hydrochloride Injection, USP;</li>\n      <li>Procan SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055112\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Class I-A</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12675549\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose must be individualized and titrated to patient's response; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia:</b> Limited data available: IV: Loading dose: 7 to 10 mg/kg infused over 60 minutes followed by a continuous IV infusion of 20 to 80 <b>mcg</b>/kg/minute; a retrospective study of 20 neonates (GA: &ge;25 weeks) reported a mean loading dose of 9.6 &plusmn; 1.5 mg/kg and a mean continuous infusion rate of 37.56 &plusmn; 13.52 <b>mcg</b>/kg/minute; <b>Note:</b> Procainamide serum concentrations were supratherapeutic in five neonates studied; four of the five were &lt;36 weeks GA and all five had CrCl &lt; 30 mL/minute/1.73m<sup>2</sup>; these results indicate that doses may need to be decreased in preterm neonates and in those with renal impairment (Moffett, 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055105\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">see &quot;Procainamide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose must be individualized and titrated to patient's response; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Antiarrhythmic:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Children and Adolescents: 20 to 30 mg/kg/day divided every 4 to 6 hours; maximum daily dose: 4000 mg/<b>day</b> (Nelson, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, I.O.: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 10 to 15 mg/kg over 30 to 60 minutes; in adults, maximum dose range: 1000 to 1500 mg (Hegenbarth, 2008; Kliegman, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Continuous IV infusion: 20 to 80 <b>mcg</b>/kg/minute; maximum daily dose: 2000 mg/24 hours (Kliegman, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Stable wide-complex tachycardia of unknown origin (atrial or ventricular) or SVT</i> (PALS [Kleinman, 2010]): Infants, Children, and Adolescents: <b>Note:</b> Avoid or use extreme caution when administering procainamide with other drugs that prolong QT interval (eg, amiodarone); consider consulting with cardiology  expert</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, I.O.: Loading dose: 15 mg/kg infused over 30-60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by &gt;50% of baseline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Antiarrhythmic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: 50 mg/kg/day divided every 3 to 6 hours <b>or</b> 0.5 to 1 g every 4 to 8 hours (Koch-Weser, 1971)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Loading dose: 15 to 18 mg/kg administered as slow infusion over 25 to 30 minutes <b>or</b> 100 mg/dose at a rate not to exceed 50 mg/minute repeated every 5 minutes as needed to a total dose of 1000 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hemodynamically stable monomorphic VT or pre-excited atrial fibrillation</i> (ACLS [Neumar, 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: Infuse 20 to 50 mg/minute <b>or</b> 100 mg every 5 minutes until arrhythmia controlled, hypotension occurs, QRS complex widens by 50% of its original width, or total of 17 mg/kg is given. Follow with a continuous infusion of 1 to 4 mg/minute. <b>Note:</b> Not recommended for use in ongoing ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) due to prolonged administration time and uncertain efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 1 to 4 mg/minute by continuous IV infusion. Maintenance infusions should be reduced by one-third in patients with moderate renal or cardiac impairment and by two-thirds in patients with severe renal or cardiac impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: There are no specific recommendations provided in the manufacturer's labeling; dose must be individualized and titrated to patient's response; monitor serum concentrations; some have suggested the following (Aronoff, 2007): <b>Note:</b> Renally adjusted dose recommendations are based on a dose of loading dose of 15 mg/kg total.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: Reduce dose to 12 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance infusion: Start at lower end of continuous infusion range of 20 to 80 <b>mcg</b>/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: Reduce dose to 12 mg/kg in severe renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance infusion: Reduce dose by one-third in patients with mild renal impairment. Reduce dose by two-thirds in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: All patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Procainamide: Moderately hemodialyzable (20% to 50%): Monitor procainamide/N-acetylprocainamide (NAPA) levels; supplementation may be necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">NAPA: Not dialyzable (0% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Procainamide/NAPA: Not peritoneal dialyzable (0% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Procainamide/NAPA: Replace by blood level during continuous arteriovenous or venovenous hemofiltration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b>  Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: Manufacturer recommends reduction in frequency of administration; specific frequency reduction not described; however, close monitoring of procainamide and NAPA concentrations and clinical effectiveness recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing (Bauer, 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (not available in the U.S.):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Child-Pugh score 8-10: Reduce initial daily dose by 25%. Monitor procainamide/NAPA concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Child-Pugh score &gt;10: Reduce initial daily dose by 50%. Monitor procainamide/NAPA concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Child-Pugh score 8-10: Reduce continuous infusion dose by 25%. Monitor procainamide/NAPA concentrations closely.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Child-Pugh score &gt;10: Reduce continuous infusion dose by 50%. Monitor procainamide/NAPA concentrations closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213516\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (10 mL); 500 mg/mL (2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213501\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055117\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Not for emergent situations; may be administered undiluted  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: <b>Note:</b> Infusion rate should be decreased if QT interval becomes prolonged or patient develops heart block; discontinue the infusion if patient develops hypotension or QRS interval widens to &gt;50% of baseline; severe hypotension can occur with rapid IV administration (Hegenbarth 2008; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neonates: Administer over 60 minutes (Moffett 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Administer over 30 to 60 minutes (Hegenberth 2008; PALS [Kleinman 2010]) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Administer at usual infusion rate: 20 to 50 mg/minute not to exceed 50 mg/minute (ACLS [Neumar 2010]; Hegenberth 2008; PALS [Kleinman 2010]) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adult: Usual rate of infusion: 20 to 50 mg/minute; do not administer faster than 50 mg/minute (ACLS [Neumar 2010]); severe hypotension can occur with rapid IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Administer via an infusion pump</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213538\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). The solution is initially colorless but may turn slightly yellow on standing. Discard solutions darker than light amber.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055116\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of life-threatening ventricular arrhythmias (FDA approved in adults); has also been used for treatment of paroxysmal supraventricular tachycardia (PSVT) and symptomatic premature ventricular contractions; and to prevent recurrence of ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">PALS guidelines: Tachycardia with pulses and poor perfusion (probable SVT [unresponsive to vagal maneuvers and adenosine and/or synchronized cardioversion]; probable VT [unresponsive to synchronized cardioversion or adenosine])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">ACLS guidelines: Treatment of the following arrhythmias in patients with preserved left ventricular function: Stable monomorphic VT; pre-excited atrial fibrillation; stable wide complex regular tachycardia (likely VT)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213591\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procanbid may be confused with probenecid, Procan SR </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pronestyl may be confused with Ponstel</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Procainamide hydrochloride is available in 10 mL vials of 100 mg/mL and in 2 mL vials with 500 mg/mL. Note that <b>BOTH</b> vials contain 1 gram of drug; confusing the strengths can lead to massive overdoses or underdoses.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">PCA is an error-prone abbreviation (mistaken as patient controlled analgesia) </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213588\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension (intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (oral), dysgeusia (oral), nausea (oral), vomiting (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Positive ANA titer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Lupus-like syndrome (increased incidence with long-term therapy or slow acetylators; syndrome may include abdominal pain, arthralgia, arthritis, chills, fever, hepatomegaly, myalgia, pericarditis, pleural effusion, pulmonary infiltrates, skin rash)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, angioedema, anorexia, aplastic anemia, arthralgia, asystole, bone marrow depression, cerebellar ataxia, confusion, demyelinating disease (demyelinating polyradiculoneuropathy), depression, depression of myocardial contractility, disorientation, dizziness, drug fever, exacerbation of cardiac arrhythmia, exacerbation of myasthenia gravis, fever, first degree atrioventricular block, flushing, gastrointestinal pseudo-obstruction, granulomatous hepatitis, hallucination, hemolytic anemia, hepatic failure, hyperbilirubinemia, hypoplastic anemia, increased serum alkaline phosphatase, increased serum transaminases, intrahepatic cholestasis, leukopenia, maculopapular rash, mania, myocarditis, myopathy, neuromuscular blockade, neutropenia, pancreatitis, pancytopenia, peripheral neuropathy,  pleural effusion, polyneuropathy, positive direct Coombs test, prolonged Q-T interval on ECG, psychosis, pruritus, pulmonary embolism, second degree atrioventricular block, tachycardia, thrombocytopenia, torsades de pointes, urticaria, vasculitis, ventricular fibrillation, ventricular tachycardia (paradoxical; in atrial fibrillation/flutter), weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213525\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to procainamide, procaine, other ester-type local anesthetics, or any component of the formulation; complete heart block; second-degree AV block or various types of hemiblock (without a functional artificial pacemaker); SLE; torsade de pointes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):<i></i>Myasthenia gravis; severe heart failure (IV); renal failure (IV); shock (IV)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213505\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias:<b> [US Boxed Warning]: Potentially fatal blood dyscrasias (eg, agranulocytosis) have occurred with therapeutic doses;</b> weekly monitoring is recommended during the first 3 months of therapy and periodically thereafter. Discontinue procainamide if this occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction disturbances: Reduce dose if first-degree heart block occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-induced lupus erythematosus-like syndrome: <b>[US Boxed Warning]: Long-term administration leads to the development of a positive antinuclear antibody (ANA) test in 50% of patients which may result in a drug-induced lupus erythematosus-like syndrome (in 20% to 30% of patients);</b> discontinue procainamide with rising ANA titers or with SLE symptoms and choose an alternative agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: Watch for proarrhythmic effects; monitor and adjust dose to prevent QTc prolongation. Avoid use in patients with QT prolongation (ACLS, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial fibrillation/flutter: May increase ventricular response rate in patients with atrial fibrillation or flutter; control AV conduction before initiating.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): Use with caution or avoid (ACLS, 2010) in patients with HF; may precipitate or exacerbate condition due to negative inotropic actions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Avoid use in myasthenia gravis; may worsen condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antiarrhythmics: Use caution with concurrent use of other antiarrhythmics; may exacerbate or increase the risk of conduction disturbances.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT<sub>c</sub> interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium metabisulfite: The injectable product may contain sodium metabisulfite which can cause allergic-type reactions, including anaphylactic symptoms and life-threatening asthmatic episodes in susceptible people; this is seen more frequently in asthmatics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution and dose cautiously; renal clearance of procainamide/NAPA declines in patients &ge;50 years of age (independent of creatinine clearance reductions) and in the presence of concomitant renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CAST trial:<b> [US Boxed Warning] In the Cardiac Arrhythmia Suppression Trial (CAST), recent (&gt;6 days but &lt;2 years ago) myocardial infarction patients with asymptomatic, non-life-threatening ventricular arrhythmias did not benefit and may have been harmed by attempts to suppress the arrhythmia with flecainide or encainide.</b> An increased mortality or nonfatal cardiac arrest rate (7.7%) was seen in the active treatment group compared with patients in the placebo group (3%). The applicability of the CAST results to other populations is unknown. Procainamide should be reserved for patients with life-threatening ventricular arrhythmias.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213576\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (major), OCT2; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213510\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12732&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class Ia). Amiodarone may increase the serum concentration of Antiarrhythmic Agents (Class Ia). Management: Avoid whenever possible. While considered contraindicated in some places, amiodarone U.S. prescribing information suggests that use could be considered under some circumstances, with careful monitoring. Reduce quinidine or procainamide dose by one third.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Procainamide. Management: Consider an alternative H2-receptor antagonist in patients taking procainamide. If combined, monitor for increased therapeutic effects/toxicity of procainamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indapamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May increase the serum concentration of Procainamide. Management: Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine.  The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: May enhance the QTc-prolonging effect of Procainamide. Management: Consider alternatives to procainamide in patients with acute lurasidone overdose.  If procainamide treatment cannot be avoided, monitor for excessive QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizolastine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Procainamide may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RaNITIdine: May increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teneligliptin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213541\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Acute ethanol administration reduces procainamide serum concentrations. Management: Avoid ethanol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213512\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10950407\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Procainamide crosses the placenta (Dumesic 1982; Oudijk 2002); procainamide and its active metabolite (N-acetyl procainamide) can be detected in the cord blood and neonatal serum (Pittard 1983). Intravenous procainamide may be considered for the acute treatment of SVT in pregnant women. Due to adverse events (lupus-like syndrome), long term therapy should be avoided unless other options are not available (Page [ACC/AHA/HRS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055111\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, blood pressure; CBC with differential and platelet counts at weekly intervals for the first 3 months of treatment, periodically thereafter, or if signs of infection, bruising or bleeding occur; antinuclear antibody test (ANA); renal function; serum drug concentrations (procainamide and NAPA) especially in patients with hepatic impairment, renal failure, or those receiving higher maintenance doses (eg, adults: &gt;3 mg/minute) for &gt;24 hours </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055115\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Timing of serum samples: Draw 6 to 12 hours after start of IV infusion; half-life is 2.5 to 5 hours in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapeutic: Optimal ranges must be ascertained for individual patients, with ECG monitoring </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procainamide: 4 to 10 mcg/mL (SI: 15 to 37 micromoles/L) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sum of procainamide and N-acetyl procainamide: 10 to 30 mcg/mL (SI: &lt;110 micromoles/L) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Toxic (procainamide): &gt;10-12 mcg/mL (SI: &gt;37-44 micromoles/L)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213504\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases myocardial excitability and conduction velocity and may depress myocardial contractility, by increasing the electrical stimulation threshold of ventricle, His-Purkinje system and through direct cardiac effects</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213524\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IM 10 to 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Children: 2.2 L/kg; Adults: 2 L/kg; decreased with congestive heart failure or shock </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 15% to 20% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via acetylation to produce N-acetyl procainamide (NAPA) (active metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procainamide (hepatic acetylator, phenotype, cardiac and renal function dependent): Children: 1.7 hours; Adults: 2.5 to 4.7 hours; Anephric: 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NAPA (dependent upon renal function): Children: 6 hours; Adults: 6 to 8 hours; Anephric: 42 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM: 15 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (30% to 60% unchanged procainamide; 6% to 52% as NAPA); feces (&lt;5% unchanged procainamide. <b>Note:</b> &gt;80% of formed NAPA is renally eliminated in contrast to procainamide which is ~50% renally eliminated (Gibson, 1977).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323724\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Procainamide HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $87.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/mL (2 mL): $75.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038779\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Biocoryl (ES);</li>\n      <li>Cardiorytmin (FI);</li>\n      <li>Gima (ID);</li>\n      <li>Kanide (LK);</li>\n      <li>Medaject[inj.] (DE);</li>\n      <li>Pasconeural-Injektopas (DE);</li>\n      <li>Procainamid (PL);</li>\n      <li>Procainamid Duriles (DE);</li>\n      <li>Procainamide Cloridrato (IT);</li>\n      <li>Procainamide Durules (NZ);</li>\n      <li>Procainamidum (PL);</li>\n      <li>Procamid depot (FI);</li>\n      <li>Procamide (BR, IT);</li>\n      <li>Pronestyl (AU, BE, CH, CL, EG, ET, GB, IE, IN, KE, LU, MY, NL, NO, QA, SG, TW, TZ, UG, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chang PM, Silka MJ, Moromisato DY, et al, &quot;Amiodarone Versus Procainamide for the Acute Treatment of Recurrent Supraventricular Tachycardia in Pediatric Patients,&quot; <i>Circ Arrhythm Electrophysiol</i>, 2010, 3(2):134-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20194798/pubmed\" target=\"_blank\" id=\"20194798\">20194798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &quot;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation of left atrial size. <i>Br Heart J</i>. 1980;44:589-595.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/7437202/pubmed\" target=\"_blank\" id=\"7437202\">7437202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA. American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. <i>Pediatrics</i>. 2008;121(2):433-443.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier;2011.  </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, Nov, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koch-Weser J and Klein SW, &ldquo;Procainamide Dosage Schedules, Plasma Concentrations, and Clinical Effects,&rdquo; <i>JAMA</i>, 1971, 215(9):1454-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/5107621/pubmed\" target=\"_blank\" id=\"5107621\">5107621</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffett BS, Cannon BC, Friedman RA, et al, &quot;Therapeutic Levels of Intravenous Procainamide in Neonates: A Retrospective Assessment,&quot; <i>Pharmacotherapy</i>, 2006, 26(12):1687-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/17125432/pubmed\" target=\"_blank\" id=\"17125432\">17125432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Procainamide hydrochloride [prescribing information]. Lake Forest, IL: Hospira, Inc; December 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raymond GG, Reed MT, Teagarden JR, Story K, Geberbauer CW. Stability of procainamide hydrochloride in neutralized 5% dextrose injection. <i>Am J Hosp Pharm</i>. 1988;45(12):2513-2517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/3228104 /pubmed\" target=\"_blank\" id=\"3228104 \">3228104 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh S, Gelband H, Mehta AV, et al, &ldquo;Procainamide Elimination Kinetics in Pediatric Patients,&rdquo; <i>Clin Pharmacol Ther</i>, 1982, 32(5):607-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/procainamide-pediatric-drug-information/abstract-text/7128001 /pubmed\" target=\"_blank\" id=\"7128001 \">7128001 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12732 Version 128.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709347\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F213545\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055112\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12675549\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055105\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F213516\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F213501\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055117\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F213538\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055116\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F213591\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F213588\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F213525\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F213505\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F213576\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F213510\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F213541\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F213512\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10950407\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055111\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1055115\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F213504\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F213524\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323724\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038779\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12732|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=procainamide-drug-information\" class=\"drug drug_general\">Procainamide: Drug information</a></li><li><a href=\"topic.htm?path=procainamide-patient-drug-information\" class=\"drug drug_patient\">Procainamide: Patient drug information</a></li></ul></div></div>","javascript":null}